Senexin B

• Background:

  Senexin B is a potent inhibitor of cyclin-dependent kinases 8 and 19.1 It suppressed tumor growth and augmented the effects of fulvestrant in ER-positive breast cancer xenografts. KD50s: CDK8 = 59 nM, CDK19 = 23 nM.2 Senexin B also showed synergistic effects with lapatinib and trastuzumab in a panel of HER2+ breast cancer cell lines. Senexin B and ALK5 inhibitor SB431542 afforded generation of pancreatic islet cells from pluripotent stem cells without any mutagenic effects.4 Combination treatment of Senexin B and Imatinib intensified apoptotic cell death in chronic myelogenous leukemia cells and prevented quiescence-mediated escape from apoptosis.5

• Conjugation:

  Unconjugated

• Buffer:

  Off-white solid

• Storage Conditions:

  -20°C